VALN News and Press, Valneva SE From 02/15/24

2024-02-15 02:02:26 ET More on Valneva: Valneva sells chikungunya vaccine priority review voucher for $103M Valneva updates 2023 guidance, sees PRV sale in early 2024 Historical earnings data for Valneva SE Financial information for Valneva SE Read ...

2024-02-05 04:31:14 ET French vaccine maker Valneva ( NASDAQ: VALN ) said on Monday it sold the priority review voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for its chikungunya vaccine for $103M.... Read the full article on Seeking Alpha For...

2023-12-29 17:38:59 ET More on Valneva Valneva: Q3 Earnings, Vaccine Valiance, Outshining Moderna Valneva SE (VALN) Q3 2023 Earnings Call Transcript Valneva's Vaccination Valor: A Buy Rating Justified Pfizer, Valneva complete recruitment for Phase 3 Lyme vacc...

2023-12-28 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-13 11:18:26 ET More on Pfizer Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Biggest stock movers tod...

2023-12-04 17:49:57 ET More on Pfizer, Valneva, etc. Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Pfizer: Between Hope, Despair, And A 5.7% Yield Pfizer: Disastrous 2023 Hits New Low With Weight Loss Drug Failure Pfizer hits new 5...

2023-11-27 04:41:15 ET More on Valneva Valneva: Q3 Earnings, Vaccine Valiance, Outshining Moderna Valneva SE (VALN) Q3 2023 Earnings Call Transcript Valneva's Vaccination Valor: A Buy Rating Justified FDA approves Valneva's world-first chikungunya vaccine ...

2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...

2023-11-14 21:40:57 ET Summary Valneva's Q3 financial results exceeded expectations, indicating a strong operational performance. The FDA approval of Valneva's chikungunya vaccine, Ixchiq, adds substantial value to the company's portfolio. Valneva's ongoing collaboration with ...

2023-11-10 04:26:41 ET More on Valneva Valneva SE (VALN) Q3 2023 Earnings Call Transcript Valneva's Vaccination Valor: A Buy Rating Justified Valneva SE (VALN) Q2 2023 Earnings Call Transcript Valneva reports 9M results FDA finds no issues in Pfizer/ ...